BINACIS – Bibliografía Nacinal en Ciencias de la Salud de Argentina

Using agents that suppress bone remodeling to treat or prevent joint disease: quo vadis?

Burr, David B.

Actual. osteol; 12 (3), 2016

Treatment of osteoarthritis (OA) with antiremodeling agents has had a mixed record of results. It is likely that remodeling suppression is only effective when used in the early phases of OA, before significant progression. Animal and human studies largely bear this out. Treatment of young mice with a RAN...

Catepsina K/antagonistas & inhibidores, Catepsina K/farmacología, Catepsina K/uso terapéutico, Clorhidrato de Raloxifeno/farmacología, Clorhidrato de Raloxifeno/uso terapéutico, Difosfonatos/farmacología, Difosfonatos/uso terapéutico, Estrógenos/uso terapéutico, Ligando RANK/antagonistas & inhibidores, Modelos Animales, Moduladores Selectivos de los Receptores de Estrógeno/farmacología, Moduladores Selectivos de los Receptores de Estrógeno/uso terapéutico, Osteoartritis/patología, Osteoartritis/prevención & control, Osteoartritis/tratamiento farmacológico, Posmenopausia, Progresión de la Enfermedad, Remodelación Ósea/efectos de los fármacos, Roedores

Fulltext

β-ARRESTIN/CONNEXIN 43 (Cx43) complex anchors ERKS outside the nucleus: a prerequisite for bisphosphonate antiapoptotic effect mediated by Cx43/ERK in osteocytes

Bisphosphonates (BPs) anti-fracture efficacy may be due in part to inhibition of osteocyte apoptosis. This effect requires opening of connexin (Cx) 43 hemichannels and phosphorylation of the extracellular signal regulated kinases (ERKs). However, unlike ERK activation by other stimuli, the Cx43/ERK pathw...